ClinicalTrials.gg
Drug

Ruxolitinib clinical trials

Also written Jakafi, INCB018424, Jakavi and INCB18424.

studies test it
302
open now
79
in phase 3
48
first study started
2002

How each study uses ruxolitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ruxolitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
16 Nov 2011 · JAKAFI · NDA 202192 (FDA, Drugs@FDA)
European Union
23 Aug 2012 · Jakavi · EMEA/H/C/002464 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ruxolitinib
204
Ruxolitinib cream
28
Oral JAK Inhibitor INCB18424
21
Ruxolitinib Phosphate
16
INCB-18424 Phosphate
13

Brand

Jakafi
74
Jakavi
26
Opzelura
7

Development codes

INCB018424
44
INCB18424
22
INC424
21

Studies by the year they started

300 studies that test it; most in 2025 (27); 2 more planned to start later

Studies that test ruxolitinib, by start year
YearStudies
20021
20074
20085
20092
20104
20119
20127
201313
201420
201513
201615
201717
201818
201922
202022
202114
202218
202321
202422
202527
202626

Who runs them

Industry 94 · Other 208

Incyte Corporation (68) · Novartis Pharmaceuticals (21) · M.D. Anderson Cancer Center (15) · Memorial Sloan Kettering Cancer Center (10) · Institute of Hematology & Blood Diseases Hospital, China (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · Fred Hutchinson Cancer Center (5) · St. Petersburg State Pavlov Medical University (5)

Often tested with

Tested in the same studies.

Cyclophosphamide (10) · Dexamethasone (7) · Methotrexate (7) · Dasatinib (5) · Tacrolimus (5) · Decitabine (5) · Adrenal Cortex Hormones (4) · Cytarabine (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

Ruxolitinib is the comparator. A study of two new drugs counts under both.

  • 2Bomedemstat · Merck Sharp & Dohme LLC · next primary completion Jul 2027
  • 1Flonoltinib · Chengdu Zenitar Biomedical Technology Co., Ltd · next primary completion Dec 2027
Reaching primary completion within a year · 32, 2 in phase 3

Studies that test ruxolitinib, phase 3 first.

Studies

Open first, then newest update. How each study uses ruxolitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 302

See all 302 studies that test ruxolitinib →

Given beside what is tested · 68 — ruxolitinib is usual care or a partner of the new treatment

Showing 20 of 68.

As the comparator · 12 — what is tested is compared with ruxolitinib

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call ruxolitinib · ClinicalTrials.gg INT005425

  • MeSH (NLM) C540383ruxolitinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 82S8X8XX8HRUXOLITINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1193326Confirmed FDA, Wikidata
  • Wikidata Q7383611ruxolitinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C77888RuxolitinibOne source FDA
  • DrugBank DB08877One source Wikidata

Also registered as ruxolitinib phosphate (UNII 436LRU32H5 · RxNorm 1193325).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.